-
Something wrong with this record ?
Cannabinoid-Induced Conditioned Place Preference, Intravenous Self-Administration, and Behavioral Stimulation Influenced by Ghrelin Receptor Antagonism in Rats
C. Charalambous, T. Havlickova, M. Lapka, N. Puskina, R. Šlamberová, M. Kuchar, M. Sustkova-Fiserova
Language English Country Switzerland
Document type Journal Article
Grant support
PROGRES Q35
PROGRES Q35
GACR 21-30795S
GACR
260533/SVV/2020
SVV
CEP Register
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
33673659
DOI
10.3390/ijms22052397
Knihovny.cz E-resources
- MeSH
- Self Administration MeSH
- Behavior, Animal drug effects MeSH
- Glycine analogs & derivatives pharmacology MeSH
- Administration, Intravenous MeSH
- Cannabinoids administration & dosage pharmacology MeSH
- Rats MeSH
- Conditioning, Operant drug effects MeSH
- Conditioning, Psychological drug effects MeSH
- Reinforcement, Psychology MeSH
- Rats, Wistar MeSH
- Receptors, Ghrelin antagonists & inhibitors MeSH
- Triazoles pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Cannabis/cannabinoids are widely used for recreational and therapy purposes, but their risks are largely disregarded. However, cannabinoid-associated use disorders and dependence are alarmingly increasing and an effective treatment is lacking. Recently, the growth hormone secretagogue receptor (GHSR1A) antagonism was proposed as a promising mechanism for drug addiction therapy. However, the role of GHS-R1A and its endogenous ligand ghrelin in cannabinoid abuse remains unclear. Therefore, the aim of our study was to investigate whether the GHS-R1A antagonist JMV2959 could reduce the tetrahydrocannabinol (THC)-induced conditioned place preference (CPP) and behavioral stimulation, the WIN55,212-2 intravenous self-administration (IVSA), and the tendency to relapse. Following an ongoing WIN55,212-2 self-administration, JMV2959 3 mg/kg was administered intraperitoneally 20 min before three consequent daily 120-min IVSA sessions under a fixed ratio FR1, which significantly reduced the number of the active lever-pressing, the number of infusions, and the cannabinoid intake. Pretreatment with JMV2959 suggested reduction of the WIN55,212-2-seeking/relapse-like behavior tested in rats on the twelfth day of the forced abstinence period. On the contrary, pretreatment with ghrelin significantly increased the cannabinoid IVSA as well as enhanced the relapse-like behavior. Co-administration of ghrelin with JMV2959 abolished/reduced the significant efficacy of the GHS-R1A antagonist in the cannabinoid IVSA. Pretreatment with JMV2959 significantly and dose-dependently reduced the manifestation of THC-induced CPP. The THC-CPP development was reduced after the simultaneous administration of JMV2959 with THC during conditioning. JMV2959 also significantly reduced the THC-induced behavioral stimulation in the LABORAS cage. Our findings suggest that GHS-R1A importantly participates in the rewarding/reinforcing effects of cannabinoids.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019187
- 003
- CZ-PrNML
- 005
- 20210830100745.0
- 007
- ta
- 008
- 210728s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22052397 $2 doi
- 035 __
- $a (PubMed)33673659
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Charalambous, Chrysostomos $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
- 245 10
- $a Cannabinoid-Induced Conditioned Place Preference, Intravenous Self-Administration, and Behavioral Stimulation Influenced by Ghrelin Receptor Antagonism in Rats / $c C. Charalambous, T. Havlickova, M. Lapka, N. Puskina, R. Šlamberová, M. Kuchar, M. Sustkova-Fiserova
- 520 9_
- $a Cannabis/cannabinoids are widely used for recreational and therapy purposes, but their risks are largely disregarded. However, cannabinoid-associated use disorders and dependence are alarmingly increasing and an effective treatment is lacking. Recently, the growth hormone secretagogue receptor (GHSR1A) antagonism was proposed as a promising mechanism for drug addiction therapy. However, the role of GHS-R1A and its endogenous ligand ghrelin in cannabinoid abuse remains unclear. Therefore, the aim of our study was to investigate whether the GHS-R1A antagonist JMV2959 could reduce the tetrahydrocannabinol (THC)-induced conditioned place preference (CPP) and behavioral stimulation, the WIN55,212-2 intravenous self-administration (IVSA), and the tendency to relapse. Following an ongoing WIN55,212-2 self-administration, JMV2959 3 mg/kg was administered intraperitoneally 20 min before three consequent daily 120-min IVSA sessions under a fixed ratio FR1, which significantly reduced the number of the active lever-pressing, the number of infusions, and the cannabinoid intake. Pretreatment with JMV2959 suggested reduction of the WIN55,212-2-seeking/relapse-like behavior tested in rats on the twelfth day of the forced abstinence period. On the contrary, pretreatment with ghrelin significantly increased the cannabinoid IVSA as well as enhanced the relapse-like behavior. Co-administration of ghrelin with JMV2959 abolished/reduced the significant efficacy of the GHS-R1A antagonist in the cannabinoid IVSA. Pretreatment with JMV2959 significantly and dose-dependently reduced the manifestation of THC-induced CPP. The THC-CPP development was reduced after the simultaneous administration of JMV2959 with THC during conditioning. JMV2959 also significantly reduced the THC-induced behavioral stimulation in the LABORAS cage. Our findings suggest that GHS-R1A importantly participates in the rewarding/reinforcing effects of cannabinoids.
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a chování zvířat $x účinky léků $7 D001522
- 650 _2
- $a kanabinoidy $x aplikace a dávkování $x farmakologie $7 D002186
- 650 _2
- $a operantní podmiňování $x účinky léků $7 D003216
- 650 _2
- $a podmiňování (psychologie) $x účinky léků $7 D003213
- 650 _2
- $a glycin $x analogy a deriváty $x farmakologie $7 D005998
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptory ghrelinu $x antagonisté a inhibitory $7 D054440
- 650 _2
- $a posilování (psychologie) $7 D012054
- 650 _2
- $a autoaplikace $7 D012646
- 650 _2
- $a triazoly $x farmakologie $7 D014230
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Havlickova, Tereza $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
- 700 1_
- $a Lapka, Marek $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
- 700 1_
- $a Puskina, Nina $u Department of Addictology, First Faculty of Medicine, Charles University, Apolinarska 4, 128 00 Prague 2, Czech Republic
- 700 1_
- $a Šlamberová, Romana $u Department of Physiology, Third Faculty of Medicine, Charles University, Ke Karlovu 4, 120 00 Prague 2, Czech Republic
- 700 1_
- $a Kuchar, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technicka 5, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Sustkova-Fiserova, Magdalena $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 5 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33673659 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100746 $b ABA008
- 999 __
- $a ok $b bmc $g 1690094 $s 1139633
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 5 $e 20210227 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a PROGRES Q35 $p PROGRES Q35
- GRA __
- $a GACR 21-30795S $p GACR
- GRA __
- $a 260533/SVV/2020 $p SVV
- LZP __
- $a Pubmed-20210728